<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01824459</url>
  </required_header>
  <id_info>
    <org_study_id>SOX-DGCA</org_study_id>
    <nct_id>NCT01824459</nct_id>
  </id_info>
  <brief_title>S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients</brief_title>
  <official_title>A Randomized, Open, Multi-center, Phase III Study of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Taiho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety of S-1+Oxaliplatin
      vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Non-intestinal Gastric
      Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint is Overall survival time (OS).Secondary is overall response rate (ORR),
      time to treatment failure (TTF),treatment to progression time (TTP)and the adverse reactions
      of the two groups (AE).

      Study design:

      This is a prospective randomized control study.

      Sample size:

      Sample size considerations were based on the survival end point. The improvement in median
      survival from 10 months in the S-1+cisplatin arm to 13 months in the S-1+oxaliplatin arm was
      considered clinically relevant in this patient population. A total of 544 patients were
      required for a two-tailed log-rank test at the 5% significance and at least 80% power. The
      planned enrolled time was 36 months and 2 years of follow up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1-1.5 year</time_frame>
    <description>OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 12 weeks till death or lost</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>1 year</time_frame>
    <description>The primary endpoint is objective response rate,which equals CR+PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to treatment failure (TTF)</measure>
    <time_frame>6 months</time_frame>
    <description>The duration is from the randomized time to treatment termination due to any reason. The reasons may include disease progression, treatment toxicity, patient selection or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment time to progression (TTP)</measure>
    <time_frame>6 months</time_frame>
    <description>The duration is from the randomized time to disease progression due to any reason except death .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE)</measure>
    <time_frame>1-1.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">544</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>S-1 + cisplatin(SP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>S-1：40~60mg bid，d1~14 q3W cisplatin：60mg/m2，iv drip ，d1,q3W Number of Cycles: until progression or unacceptable toxicity develops.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S-1+Oxaliplatin（SOX）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-1：40~60mg bid，d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W Number of Cycles: until progression or unacceptable toxicity develops.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>S-1：40~60mg bid，d1~14 q3W</description>
    <arm_group_label>S-1 + cisplatin(SP)</arm_group_label>
    <arm_group_label>S-1+Oxaliplatin（SOX）</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W</description>
    <arm_group_label>S-1+Oxaliplatin（SOX）</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>cisplatin：60mg/m2，iv drip ，d1,q3W</description>
    <arm_group_label>S-1 + cisplatin(SP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. histologically confirmed unresectable advanced or recurrent diffuse-type or mixed-type
             gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.

          2. 18 years old to 75 years old, able to conduct oral administration.

          3. Measurable disease or non-measurable but evaluable disease, according to the Response
             Evaluation Criteria in Solid Tumours(RECIST 1.1)

          4. No palliative chemotherapy and radiotherapy. Previous adjuvant or neoadjuvant
             chemotherapy , if applicable, more than 12 months.

          5. ECOG systemic status score of 0 to 2.

          6. normal organ function, that meet the following criteria:

               1. ALT and AST(≤2.5 times ULN (≤5 times ULN in patients with liver metastases)

               2. ALP ≤ 2 times ULN ; (for patients with liver metastases can be no limit to the
                  ALP).

               3. Total bilirubin ≤ 1 times ULN.

               4. Absolute neutrophil count ≥ 2.0 × 10^9 / L.

               5. Platelet count ≥ 100 × 10^9 / L.

               6. Hemoglobin ≥ 80g / L.

               7. Creatinine ≤ 1.25 times ULN.

               8. The estimated creatinine clearance ≥ 60 mL/min (Cockcroft-Gault formula).

          7. Signed informed consent, treatment, follow-up and inspection in accordance with the
             study protocol.

          8. Life expectancy greater than 3 months.

          9. At least 3 weeks after major surgery.

        Exclusion Criteria:

          1. Previous adjuvant or neoadjuvant chemotherapy within the prescribed time

          2. the investigator determines that the patient is not suitable for participation in this
             study, and specifically includes (but is not limited to):

               1. The past five years there have been other malignancies, but after appropriate
                  treatment of cervical carcinoma in situ and non-melanoma skin cancer.

               2. brain metastases or leptomeningeal metastasis.

               3. myocardial infarction (within the past six months), severe unstable angina,
                  congestive heart failure.

               4. Serious complications (including paralytic ileus, intestinal obstruction,
                  interstitial pneumonia, lung fibrosis, beyond the control of diabetes, renal
                  insufficiency and cirrhosis of the liver, etc.).

               5. Chronic nausea, vomiting, or diarrhea (per day greater than or equal to 4 times
                  or watery stools).

               6. Gastrointestinal bleeding, and need for frequent blood transfusions.

               7. human immunodeficiency virus (HIV) carrier or suffering from AIDS (AIDS).

               8. Suffering from a mental illness.

               9. neuropathy severity ≥grade 2 .

              10. Infectious disease or inflammation, body temperature ≥ 38 ℃.

          3. Cisplatin, oxaliplatin, or S-1 allergy.

          4. Pregnancy or breast-feeding women.

          5. refused to take appropriate contraceptive measures (including male patients).

          6. Under experimental drug within 4 weeks.

          7. Under other anti-cancer treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ruihua xu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>SunYat-sen University Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruihua xu, Professor</last_name>
    <phone>862087343228</phone>
    <email>xurh@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>yuhong li, Professor</last_name>
    <phone>13602755671</phone>
    <email>liyuhong@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruihua Xu, phD</last_name>
      <phone>86-20-87342479</phone>
      <email>xurh@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2013</study_first_submitted>
  <study_first_submitted_qc>April 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2013</study_first_posted>
  <last_update_submitted>March 11, 2018</last_update_submitted>
  <last_update_submitted_qc>March 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Ruihua Xu</investigator_full_name>
    <investigator_title>vice president of SunYat-sen University Cancer Center,head of medical oncology department</investigator_title>
  </responsible_party>
  <keyword>Non-intestinal type gastric cancer</keyword>
  <keyword>Advance Gastric Cancer</keyword>
  <keyword>Recurrent Gastric Cancer</keyword>
  <keyword>Gastroesophageal Junction Adenocarcinoma</keyword>
  <keyword>SOX, S-1+Oxaliplatin</keyword>
  <keyword>OS,</keyword>
  <keyword>ORR,</keyword>
  <keyword>TTP,</keyword>
  <keyword>TTF,</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

